Kiniksa Pharmaceuticals to Present at 40th Annual J.P. Morgan Healthcare Conference
Kiniksa Pharmaceuticals (KNSA) announced its participation in the 40th Annual J.P.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Kiniksa Pharmaceuticals (KNSA) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022, at 1:30 p.m. ET. A live webcast of the presentation will be available on Kiniksa's website, with replays accessible within 48 hours post-event. The firm focuses on developing therapeutic medicines for diseases with significant unmet needs, featuring assets like ARCALYST® and mavrilimumab. For more details, visit www.kiniksa.com.
Details
News Market Reaction – KNSA
The recorded move for KNSA in the trading session of this news was -5.42%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
HAMILTON, Bermuda, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 1:30 p.m. Eastern Time.
A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST® (rilonacept), mavrilimumab, vixarelimab and KPL-404, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.
ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.
| Every Second Counts! ® Kiniksa Investor and Media Contact Rachel Frank (339) 970-9437 rfrank@kiniksa.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.